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 Over the past few decades, the rise of multidrug resistant (MDR) microorganisms has 
grown from an isolated concern to a massive public health crisis. It has become imperative that 
scientists look for new ways to combat this issue. Due to the selective pressures of competition, 
bacteria and other microbes possess a host of defenses and weapons designed to exploit 
vulnerabilities in other microorganisms. Consequently, the study of these systems and microbial 
interactions has much to reveal in the search for novel antimicrobial treatments. Previous 
research from our laboratory has discovered that both Alcaligenes faecalis and Alcaligenes 
viscolactis, two rarely studied and generally non-virulent bacteria, exert a microbicidal effect on 
Candida albicans and Staphylococcus aureus, two pathogenic and frequently drug-resistant 
organisms. In this study, we confirmed that these effects are via a live-cell, contact-dependent 
mechanism and showed that both Alcaligenes species continue to inhibit S. aureus in both 
planktonic and biofilm forms of growth. Additionally, we found that A. faecalis and A. 
viscolactis have the ability to target Gram-positive bacteria outside the genus Staphylococcus and 
certain Gram-negative species as well as Candida glabrata. This study also provides evidence 
for the existence of a Type VI Secretion System in both A. faecalis and A. viscolactis, which may 
explain their antimicrobial phenotype. Despite efforts to identify the genetic elements involved 
via transposon and site-directed mutagenesis, the mechanism of these interactions remain elusive 
due to the difficulty of gene transfer in these organisms. We hope these results will increase 
current knowledge of Alcaligenes’ capabilities and genetic composition as well as establish the 
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History of Antibiotics & Current Antibiotic Crisis 
 
Sir Alexander Fleming’s discovery of Penicillin in 1928 unleashed on the world a 
seemingly unstoppable power that helped transform medicine into its modern form as we know it 
today [1]. Bacterial infections once devastating to the human body became immediately 
vulnerable to these new drugs as an avalanche of new antibiotic classes and derivatives were 
discovered, developed, and synthetically modified. While antibiotics have undoubtedly saved 
millions of lives since their discovery, their efficacy has been challenged by their intended 
targets from the very beginning. In 1940, three years before Penicillin reached mainstream usage 
as a treatment, Penicillin-resistant strains of bacteria had already been isolated [1]. In 1962, two 
years after the introduction of Methicillin, deadly Methicillin-resistant strains of Staphylococcus 
aureus were discovered [1]. While decades of new antibiotic discoveries and advancement have 
helped keep this problem at bay, it has now resurfaced in recent years as one of the most pressing 
crises of modern medicine for many reasons. A 2013 report by the World Health Organization 
declared antibiotic resistance to be a worldwide, catastrophic threat with over 2 million cases and 
23,000 mortalities occurring from resistant infections in the United States alone [2].  
While antibiotic resistance is an unavoidable product of bacterial evolution and the 
selective pressures of exposure to antibiotics, it has been drastically precipitated by inappropriate 
prescribing practices, extensive agricultural use, and the collapse of antibiotic research and 
development in the pharmaceutical industry due to lack of financial profitability and shortage of 
scientific innovation and new discoveries [3]. Consequently, today’s research has begun to shift 
to a focus on alternatives to traditional antibiotics including bacteriophage therapy, predatory 




the potency of antibiotics [4]. As a result, it is imperative that novel methods of bacterial 
inhibition continue to be explored, as is the aim of this thesis. 
Development of Antifungal Resistance 
 
 Unfortunately, the unopposed expansion of antimicrobial-resistance has not been limited 
to antibiotics, but has also penetrated the sphere of antifungal treatment. Unlike antibiotics, 
antifungal agents are relatively few in number and even more difficult to develop. As eukaryotes, 
both fungi and humans employ similar cellular machinery; therefore, antifungals approved for 
clinical application must exhibit high selectivity and low toxicity, ensuring no disruption to the 
host’s cells during treatment [5]. Only four major classes of antifungal agents currently exist for 
invasive infections: polyenes, flucytosine, azoles, and echinocandins [5]. Since the introduction 
of triazoles in the early 1990s, resistance in Candida and Aspergillus species has become a 
global threat [6]. Even with treatment, the mortality of patients with fungal infections remains 
high, with mortality rates of 30% and 50% for aspergillosis and candidemia patients respectively 
[7,8]. Moreover, since 2006, no new classes of antifungals have been approved as of 2015 [8]. 
Given the paucity of available drugs and the rapid emergence of resistant strains, advancement 
and innovation in anti-fungal agents will continue to be an urgent need in the coming years. 
Polymicrobial Interactions 
 
 One promising area in the search for new mechanisms of microbial inhibition is that of 
polymicrobial interactions. Polymicrobial interactions between organisms can be studied several 
ways in vitro via liquid co-culture assays, spot test analyses, and biofilm co-cultures, which can 
better mimic microbial interactions as they occur in vivo. In recent years, there has been a 
growing awareness that microbes rarely live in isolated, planktonic colonies but instead coexist 




some cases, interactions such as those between Pseudomonas aeruginosa and Staphylococcus 
aureus are synergistic, increasing the invasiveness and virulence of infection when present 
together [10]. In other cases, the interactions are antagonistic such as in Bdellovibrio and 
Micavibrio-style predation, parasitism between bacteriophages and bacteria, competition, or 
amensalism [11,12]. Even outside of the human body, microbes such as bacteria often live in 
large, heterogenous communities, and competition for resources drives the evolution of many 
antimicrobial systems and production of compounds such as ribosomally synthesized peptides or 
proteins called bacteriocins [13,14]. With more than 99% of bacterial species producing at least 
one bacteriocin, most still unidentified, use of bacteriocins as replacements for antibiotics seems 
an incredibly promising area of research [14]. There are still many potential barriers yet to be 
overcome. These include the high cost of commercial production, degradation via proteolytic 
activity, and narrow spectrum activity for most tested bacteriocins [15]. Fortunately, antagonistic 
interactions among microbes are not solely limited to bacteriocin production and therefore 
remain a critical area of focus for the exploration of new inhibitory mechanisms [16]. Other 
known modes of inhibition include the aforementioned Bdellovibrio-style predation, Type III 




 The research involved in this thesis centers on two species of bacteria in the genus  
Alcaligenes, the first being Alcaligenes faecalis. A. faecalis is a motile, peritrichous, Gram-
negative bacillus found in aqueous environments, soil, and human intestinal flora [20]. It is also 
an aerobic, catalase and oxidase positive nonfermenter, though it can grow in anaerobic 




optimally at temperatures between 25°C and 37°C, usually occurring singly but occasionally in 
pairs or chains [22]. While generally nonpathogenic, A. faecalis can in extremely rare cases 
induce nosocomial infections in immunocompromised patients and has been implicated in 
chronic otitis, endocarditis, endophthalmitis, and bacteremia, though with mostly favorable 
outcomes after treatment [20]. Most recently, a strain of A. faecalis has been found to have 
nematicidal effects on Caenorhabditis elegans via an extracellular serine protease virulence 
factor [23].  
Alcaligenes viscolactis 
 
 Unlike its relative, few records of Alcaligenes viscolactis are found in scientific literature. 
A. viscolactis is an aerobic, nonmotile, Gram-negative, and almost spherical rod with an optimal 
growth temperature of 10°C to 20 °C [24]. It is also found in aqueous environments, and its size 
is roughly 0.5-1.0 by 0.8-2.6 μm [24]. Most notably, A. viscolactis is known to produce ropiness 
in milk; however, there is no record of pathogenicity in this organism, opportunistic or 
otherwise, making it an ideal candidate for potential use as an inhibitor of a variety of pathogenic 
organisms [24].  
Staphylococcus aureus 
 
 Despite its commensal presence in approximately 30% of humans, Staphylococcus 
aureus is a common source of nosocomial and community-acquired infections [25]. While it is 
most commonly implicated in skin infections such as abscesses and boils, this Gram-positive 
coccus possesses a host of virulence factors such as toxins and immunoglobulin-binding proteins 
and can cause serious, invasive infections, leading to sepsis and even death [26]. Since the first 
appearance of Methicillin-resistant strains of S. aureus (MRSA) over fifty years ago, MRSA has 




antibiotics and failure to identify suitable antigens for vaccine development [25]. Despite a 
substantial decline in MRSA bloodstream infections from 2005 to 2012, the decrease has slowed 
remarkably since then, with 72,444 cases of invasive MRSA in the U.S. in 2014 [27,28]. 
Traditionally, severe MRSA infections have been effectively treated with Vancomycin; however, 
the rise of Vancomycin intermediate-resistant S. aureus (VISA) and Vancomycin resistant S. 
aureus (VRSA) poses a severe threat around the globe [27]. Another key feature of S. aureus is 
its ability to form a biofilm composed of polysaccharides, DNA, and protein [29]. These biofilms 
can attach to bone, heart valves, and implanted materials, leading to chronic infections [29]. 
Additionally, S. aureus biofilms decrease the organism’s susceptibility to antibiotics and 
weakens immune responses, resulting in increased virulence [29].  
Candida albicans 
 
 Like S. aureus, the fungi, Candida albicans, is a commensal organism, residing in the 
gastrointestinal and genitourinary tracts of approximately 70% of humans [30]. In 
immunocompromised patients, C. albicans often becomes an opportunistic pathogen. Candida is 
one of the four most common causes of hospital-acquired bloodstream and cardiovascular 
infections in the U.S., resulting in mortality rates as high as 50% [30]. C. albicans forms 
protective biofilms and has been developing increasingly high levels of resistance to anti-fungal 
drugs, a major cause of concern in the medical and scientific communities. It also exhibits 
morphological switching, primarily between its yeast and hyphal forms, which plays a critical 
role in its virulence [30].  
Type VI Secretion Systems 
 Due to prior observations that Alcaligenes 1) inhibits other organisms via cytolytic effects 




prokaryotic and eukaryotic organisms, we have hypothesized that the presence of a secretion 
system may be implicated in this phenomenon. Although Type III, IV, and VI secretions systems 
are able to inject effector molecules directly into other cells via a syringe-like apparatus, many 
with microbicidal effects, only the Type VI secretion system (T6SS) has been currently shown to 
kill both bacterial and fungal species [31,32]. Since its discovery in Vibrio cholerae, the T6SS 
has been found in around 25% of all Gram-negative bacteria [33] and confers an incredible 
advantage on organisms competing for resources. While principally thought of as an antibacterial 
weapon, the T6SS has many diverse functions and can play an important role in virulence and 
pathogenesis, as it does with Pseudomonas aeruginosa in cystic fibrosis patients [33]. More 
recently, this system has been shown in Serratia marcescens to target fungal cells, including 
those of pathogenic Candida species, in addition to bacterial cells, highlighting its capability as 
both an antibacterial and antifungal weapon [34]. T6SS machinery is composed primarily of a 
membrane-spanning unit and a tube-like structure that closely resembles a bacteriophage tail. As 
the outer sheath contracts, the inner tube and spike propels out of the bacterium and punctures 
the membrane of the target organism, delivering effector molecules that lead to disruption or 
lysis of the cell [33]. These effector molecules generally target conserved structures such as the 
cell wall, membrane compartment, nucleic acids, or cytoskeletal components [33]. Immunity 
proteins to specific effector molecules protect the organism from self-destruction [33]. In Vibrio 
cholerae, the T6SS is regulated by quorum sensing, catabolite repression, and environmental 
conditions, among a host of other factors [35]. It is chromosomally encoded within large, 
variable clusters that contain thirteen essential core genes labeled TssA through TssM, which 




faecalis or A. viscolactis has been previously recorded or characterized in scientific literature, 
our observations suggest the possibility that this system or one analogous to it may be involved.    
Prior and Present Research 
Research in our lab has uncovered several previously unknown features regarding A. 
faecalis and A. viscolactis. First, both Alcaligenes species were shown to have apparent 
bactericidal effects in a concentration-dependent manner on Staphylococcus aureus, 
Staphylococcus epidermidis, and other Staphylococcal species in planktonic form [37]. 
Additionally, heat-killed and cell-free supernatant tests of A. faecalis and A. viscolactis on S. 
aureus were determined to have no inhibitory effect, proving that this phenomenon is dependent 
on live Alcaligenes cells and on cell-cell contact [37]. Furthermore, our lab has discovered that 
A. faecalis and A. viscolactis also inhibit growth of Candida albicans in both clinical and 
laboratory isolates as well as hyphal and yeast-locked strains [38]. This inhibition is dependent 
on live-cell interaction, suggesting that the mechanism may likely be the same in the killing of 
both Staphylococcal spp. and C. albicans [38]. These discoveries show great potential in 
uncovering therapeutic targets for attacking these pathogenic and often drug-resistant organisms 
and possibly even for the use of select Alcaligenes strains to kill them directly. For these reasons, 
it is highly desirable to uncover the exact mechanism by which Alcaligenes kills its targets.  
 The objectives of this thesis project were fourfold: 1) to carry out preliminary testing of 
A. faecalis and A. viscolactis’ ability to inhibit biofilm growth of S. aureus, 2) to expand our 
analysis outside of C. albicans and Staphylococcal species to determine whether other organisms 
are susceptible to Alcaligenes, 3) to uncover the genetic elements responsible for this 




Alcaligenes contains T6SS machinery and, if present, its potential contribution to our 
observations.   
MATERIALS AND METHODS 
Strains Characteristics Reference 
A. faecalis  
ATCC® 8750™ 
used for biofilm & spot assays, screening for 





used for biofilm & spot assays, screening for 
inhibition, mutagenesis, & genetic analysis 
 
S. aureus  
ATCC® 25923™ 
used for biofilm assays, screening for inhibition  
S. aureus  
Clinical isolate 
used for biofilm assays, screening for 
inhibition, obtained from Quillen COM 
 
C. albicans  
SC5314 
 
Used for supernatant spot assays   
E. coli HB101  host for pRK2013 helper plasmid, used for 
triparental mating 
Ditta et al. 1980 
E. coli BW20767 host for pRL27-Tn5 plasmid, used for 
transposon mutagenesis   
Nguyen et al. 2016 
E. coli SM10λpir used for biparental conjugation  
Plasmids   
pRL27 Tn5 transposon delivery vector, KanR,  Nguyen et al. 2016 
pEX18Gm general cloning vector, GmR Hoang et al. 1998  
pEX18GmΔVgrG pEX18Gm containing SOE product deletion of 
VgrG gene  
This work  
pRK2013  Helper plasmid for triparental mating, KanR Ditta et al. 1980  
Table 1: Primary bacterial strains and plasmids.   
Growth Conditions 
Unless otherwise noted, all bacterial strains (Table 1) except A. viscolactis were grown in 
broth cultures at 37°C on a shaker deck set to 250 RPM. Liquid cultures of A. viscolactis were 
grown at laboratory room temperature, approximately 20-25 °C, on a shaker set to 40 RPM 




same temperature range. The primary medium for most strains was Luria-Bertani (LB) broth for 
liquid cultures and LB agar for plated cultures. Other media and conditions used will be 
discussed under their specific protocols. 
Alcaligenes - S. aureus Biofilm Interactions 
 Liquid cultures of A. faecalis, A. viscolactis, laboratory S. aureus, and clinical S. aureus 
were prepared via inoculation in 5 mL tubes of LB broth and incubated on a rotary shaker for 
approximately 24 hours.  
 Using a spectrophotometer set to 600 nm (OD600), the absorbance of the overnight 
cultures were taken and used to prepare standardized co-cultures with a 10:1 ratio of Alcaligenes 
to S. aureus in 5mL LB tubes, along with controls of clinical and laboratory S. aureus alone in 
equivalent amounts. One mL of each preparation was pipetted into separate wells on a six well 
plate. Additionally, a slide cover slip was placed in one control and one co-culture well. The well 
plate was placed in a 37°C incubator for approximately 24 hours.  
 After incubation, the residual liquid in each well was poured off, and the biofilms 
carefully washed once with 1 mL of phosphate buffer solution (PBS). Another 1 mL of PBS was 
added to each of the wells, and the biofilm was scraped into the solution with a pipette. Tenfold 
serial dilutions of the biofilms were performed using PBS. The dilutions were plated on Mannitol 
Salt Agar (MSA), a selective and differential medium used for Staphylococcus species that 
prevents Alcaligenes from growing. The MSA plates were subsequently placed at 37°C 
overnight, and colony counts were carried out the following day to determine relative biofilm 
growth of S. aureus in the experimental vs control conditions. This procedure was later modified 




us to ascertain whether increasing the concentration of Alcaligenes cells decreases number of 
viable S. aureus colonies in biofilms.  
 In the wells containing the cover slips, the coverslip containing the intact biofilm was 
carefully removed, Gram-stained, and visualized under a microscope at 100x magnification.   
Co-culture Supernatant Spot Testing 
 
Overnight cultures of A. faecalis, A. viscolactis, S. aureus, and C. albicans were 
prepared. As with the biofilm procedure, a spectrophotometer was used to create co-culture 
samples with a 10:1 ratio of Alcaligenes to S. aureus or C. albicans. Of note, co-cultures with C. 
albicans were prepared in BHI media for better growth. After 24 hours of growth, cell-free 
supernatant from the co-cultures and from Alcaligenes, S. aureus, and C. albicans single cultures 
were obtained by pelleting the cells on a tabletop centrifuge then filter sterilizing the remaining 
solution with a 0.45 μm filter. Afterwards, 20 μL of the supernatant from the co-cultures were 
spotted onto lawns of the test organism (S. aureus or C. albicans) along with controls of live 
Alcaligenes cells, Alcaligenes supernatant, and S. aureus/C. albicans supernatant.  
Broad-Spectrum Spot Testing  
 Spot tests were performed by pipetting 20 μL of an overnight culture of A. faecalis and A. 
viscolactis on an LB agar plate streaked with a lawn of the test organism. After allowing the 
plates to dry, they were placed at 37°C for 24-48 hours. Lawns of Rhizobium leguminosarum 
ATCC #14479 were streaked on Congo Red and incubated at 30°C while Candida glabrata was 
grown on BHI at 20-25°C because of different nutrient and growth requirements. Zones of 
inhibition, if present, were measured and recorded.  
 New A. faecalis strains C19593 and ATCC #35655 were tested for antibiotic 




incubated overnight. Liquid cultures of the strains were prepared, and 20 μL of each was spotted 
onto a lawn of S. aureus clinical strain to determine if these other strains also possess the 
inhibitory phenotype observed in A. faecalis ATCC #8750.  
Transposon Mutagenesis  
Overnight liquid cultures of A. faecalis, A. viscolactis, and E. coli BW20767 carrying the 
pRL27 plasmid were prepared in 5 mL of LB broth. Several methods were then used to induce 
mating. All overnight incubations were carried out at 37°C except with A. viscolactis cultures.   
Cross Hatch Technique: Each Alcaligenes sp. was crossed with the pRL27 strain on an 
LB agar plate using sterile cotton swabs. After incubation for 24 hours, 1 mL of PBS was added 
to the plate, and the colonies were scraped into the solution using a sterilized hockey stick.100 
μL of this solution was then plated onto an LB agar plate containing Kanamycin and Ampicillin 
(LB + KA) at concentrations of 50 μg/ml each and incubated for 24 hours. Isolated colonies were 
transferred to a fresh LB + KA plate using sterile toothpicks and allowed to grow again before 
spot testing against S. aureus.  
Liquid Co-culture Technique: 10 μL of pRL27 and 30 μL of Alcaligenes were added to a 
5 mL LB tube and placed on a shaker. After 24 hours of growth, 100 μL of the co-culture was 
plated on LB + KA and again incubated. As before, isolated colonies were transferred to a fresh 
LB+KA and allowed to grow before phenotype screening.  
Spot Co-culture Technique: Using overnight liquid cultures, 500 μL of Alcaligenes and 
pRL27 were mixed in a microcentrifuge tube and pelleted in a tabletop centrifuge. After 
resuspending in 200 μL of LB, 20 μL of the concentrated co-culture was spotted onto a fresh LB 




and plated on LB + KA selective media. Further isolation of suspected mutants were carried out 
as in the previous techniques.  
In Silico Analysis of A. faecalis Genome Sequences  
 Using the National Center for Biotechnology Information (NCBI) GenBank, multiple 
strains of A. faecalis were analyzed for presence of T6SS genes. Three strains, NTCC #10388, 
BBD4, and ZD02, were primarily analyzed and later used to construct primers. A. faecalis 
ATCC# 8750, our lab’s strain, has not been fully sequenced and could not be used for complete 
genetic analysis.   
Primer Design 
 The primers used in this study (Table 2) were designed largely by hand with the help of 
NCBI Primer Blast and New England Biolab’s Tm Calculator.   
Name  Sequence (5’ – 3’)        Use 
VgrG-par-F GCTGACAGAACGCCTTGTAC Partial VgrG amplification 
VgrG-par-R CGATACGTGTAGAAGCGGTC Partial VgrG amplification 
VgrG-tot-F GCTGACAGAACGCCTTGTAC Total VgrG amplification 
VgrG-tot-R GATACACCGCACTGGTCTTG Total VgrG amplification 
AF-Hcp-F TCCAGTCCTTTTCATGGGGC Hcp Amplification 
AF-Hcp-R TGCTTGATATCCCAGGCCAC Hcp Amplification 








Downstream SOE Forward 
Primer 
SOER1                              GCTATCTAGATGGACGTTGCCCAAATACAGC Downstream SOE Reverse 
Primer 







 Genomic extraction was completed using 2 mL of an overnight culture of A. faecalis and 
a Promega Wizard gDNA purification kit. Extracted gDNA was tested for purity and 
concentration using a Thermo Scientific nanodrop and stored at 4°C or -20°C.  
Detection of VgrG via PCR and Electrophoresis 
 Aliquots containing primers pairs VgrG-par-F/VgrG-par-R and VgrG-tot-F/VgrG-tot-R 
along with 1 μg of gDNA, nuclease free H2O, and NEB 2X Taq Polymerase Master Mix were 
prepared to amplify partial and total sequences of the VgrG gene respectively. PCR parameters 
were adjusted until optimal conditions were reached (Table 3). PCR products were loaded on a 
1% agarose gel containing Ethidium Bromide at a concentration of 0.7 μg/mL, run at 125V for 
40-45 minutes, and visualized under UV light. The Hcp gene was later amplified under the same 
PCR conditions (Table 3).  
Step Temp Time 
Initial Denaturation 95°C 
 
2 minutes 
34 cycles  95°C 30 seconds  
 52°C 30 seconds  
 72°C  
 
1 minute/kb  
Final Extension  72°C 5 minutes  
Hold  4°C  ∞ 
Table 3: PCR thermocycler protocol for amplification of VgrG and Hcp genes.  
DNA Extraction & Sequencing 
 Following amplification, 50 μL aliquots of PCR product were extracted from a 1% 
agarose gel containing no Ethidium Bromide and purified using a Thermofisher gel extraction 
kit. Purity and concentration of the extracted DNA were analyzed by nanodrop and by running 2-




of Medicine’s Molecular Biology Core Facility for sequencing along with 15 μL each of the 
appropriate primers diluted to a working concentration of 3μM.   
Analysis of DNA Sequences 
Sequencing results were cleaned and analyzed using NCBI Nucleotide Blast, Emboss 
Merger, EMBOSS Needle, and a reverse complement generator acquired from 
Bioinformatics.org.  
Splicing by Overlap Extension 
 Splicing by Overlap Extension (SOE) is a method in which regions flanking the gene of 
interest (approximately 1,000 base pairs (bp) upstream and downstream) are amplified via PCR 
and fused together, thereby deleting out the gene [42]. This construct can then be ligated into a 
vector and transferred into the species containing the gene of interest. From there, homologous 
recombination replaces the original sequence, creating a knockout mutant. This technique was 
used in an attempt to delete the VgrG gene in A. faecalis. Primers were designed using the A. 
faecalis genomic sequences noted earlier and previously designed overlap/restriction enzyme 
sequences [43]. Primer pairs SOEF1 – SOER2 were used to amplify a 944 bp sequence upstream 
of VgrG while primer pairs SOEF2 – SOER1 were used to amplify a 1,041 bp sequence 
downstream using the PCR parameters outlined previously (Table 3). Once the upstream and 
downstream products were purified via gel extraction, a second, two-step PCR reaction was run, 
splicing the fragments together and generating an approximately 2,000 bp product with a 
deletion of VgrG (Tables 4 & 5). Following a second purification, the ends of this 2 kb fragment 
and extracted pEX18Gm plasmid vector were digested using KpnI and XbaI restriction enzymes.  
pEX18Gm is a plasmid vector containing a Gentamicin (GmR) resistance marker, pUC 




both the vector and insert, ligation using T4 DNA ligase was carried out using a 1:3 picomolar 
ratio of vector to insert following a protocol from New England Biolabs (NEB). Integration of 
the SOE product into pEX18Gm formed pEX18GmΔVgrG. Competent NEBα5 E. coli cells were 
prepared using the Rubidium Chloride (RbCl2) protocol obtained from Mcmanus Lab. The 
ligation product was used to transform pEX18GmΔVgrG into competent NEBα5 cells via a heat 
shock protocol obtained from NEB. Cells successfully transformed with pEX18GmΔVgrG were 
isolated using blue-white screening on LB agar plates containing 20 μg/mL of Gentamicin and 
20 μg/mL of 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-gal).  
 Plasmid vector pEX18Gm contains a LacZα gene, which encodes for β-galactosidase, at 
its multiple cloning site [41]. When treated with X-gal, cells containing the non-recombinant 
plasmid express a functional β-galactosidase that cleaves X-gal, forming a bright blue pigment. 
Insertion of DNA into the multiple cloning site disrupts the LacZα gene, and the blue pigment is 
not produced upon treatment with X-gal and appear white [44]. White colonies were re-plated, 
and presence of the SOE product was confirmed by colony PCR using primer pair SOEF1-
SOER1. 
Mixture 1 (25 μL) Step Temp Time 
Upstream Template (2 μL) Initial Denaturation 95°C 
 
3 minutes 
Downstream Template (1 μL) 15 cycles  95°C 45 seconds  
  52°C 45 seconds  
Taq 2X Master Mix (12.5 μL)  72°C  
 
2.25 minutes  
Sterile H2O (9.5 μL) Final Extension  72°C 10 minutes  
 Hold  4°C  ∞ 









Mixture 2 (50 μL) Step Temp Time 
Product from Reaction 1 (25 μL) Initial Denaturation 95°C 
 
1 minutes 
SOEF1 Primer (0.5 μL) 30 cycles  95°C 45 seconds  
  52°C 45 seconds  
SOER1 Primer (0.5 μL)  72°C  
 
2.25 minutes  
Taq 2X Master Mix (12.5 μL) Final Extension  72°C 10 minutes  
Sterile H2O (11.5 μL) Hold  4°C  ∞ 
Table 5: Crossover reaction 2 setup and thermocycler protocol.  
Transfer of pEX18GmΔVgrG to A. faecalis 
NEBα5 cells harboring pEX18GmΔVgrG were then used for triparental conjugation with 
pRK2013 and A. faecalis ATCC #8750 to transfer the deletion product to A. faecalis. Overnight 
cultures of the three strains were grown in antibiotic-containing LB broth, ensuring their purity. 
NEBα5 was grown in 20 μg/mL of Gentamicin, pRK2013 in 50 μg/mL of Kanamycin, and A. 
faecalis in 35 μg/mL of Ampicillin. One microliter of each culture was pelleted using a tabletop 
centrifuge and washed twice with sterile 0.85% NaCl to remove any residual antibiotics. After 
resuspending in 200 μL of saline, 100 μL of each strain was mixed, pelleted, and resuspended in 
30 μL of saline or filter sterilized PBS. This mixture was spotted in 10-15 μL aliquots either 
directly onto LB agar or onto a 0.45 μm nitrocellulose filter disk resting on the agar, and the 
plates were allowed to incubate for 24 hours at 37 °C. After incubation, the mixture was 
resuspended in 1 mL of PBS by using an inoculation loop or vortexing the filter disk. Tenfold 
dilutions were then performed and plated on LB + Gm20 agar. Following incubation for 24-48 




pEX18GmΔVgrG plasmid was also transformed into RbCl2 competent E. coli SM10λpir cells by 
heat shock and biparental mating was carried out following the same procedure as above without 
use of the pRK2013 strain.  
RESULTS & DISCUSSION 
Biofilm Interactions  
 
 Results from the biofilm co-culture assays reveal that both A. faecalis and A. viscolactis 
are able to outcompete S. aureus when grown together and cause a significant reduction in the 
growth of viable S. aureus cells during the attachment phase of biofilm formation. Co-culturing 
clinical S. aureus with A. viscolactis at a 1:10 ratio resulted in a 97.2% decrease in viable cells 
while co-culturing S. aureus with A. faecalis at the same ratio resulted in a 96.1% decrease (Fig. 
1 & 2). Doubling the concentration of A. viscolactis and A. faecalis resulted in S. aureus 
reductions of 98.3% and 97.6% respectively (Fig. 1 & 2). Surprisingly, tripling the concentration 
of Alcaligenes failed to significantly decrease S. aureus growth even further and the number of 
surviving S. aureus cells rose slightly in the assays with A. faecalis. This demonstrates that while 
inhibition of S. aureus biofilms by Alcaligenes follows a concentration-dependent manner, this 
effect is limited and seems to slow or stop once a certain concentration of cells is reached. A 
plausible explanation for this observation may be that at high concentrations, rapid depletion of 
resources occurs, which in turn may effect Alcaligenes’ ability to prey on other organisms. 
Gram-stains of the control vs experimental co-cultures visualized with light microscopy at 100x 
magnification demonstrates the effectiveness of Alcaligenes at disrupting S. aureus biofilm 
growth (Fig. 3). Of note, these results show that A. viscolactis, whose optimum temperature 








Figure 1: Viable S. aureus colonies on Mannitol Salt Agar after 24 hours at 37°C from washed 
biofilms. Biofilms were grown for 24 hours at 37°C under control conditions with our clinical S. 
aureus strain alone and under experimental conditions with our clinical S. aureus strain co-
cultured with one, two, and three times concentrations of A. viscolactis. Mean log10 CFU/mL 
data were obtained from three separate trials, and statistical analysis was performed using one-
tailed, unpaired Student T-tests comparing the control condition to each of the three experimental 
conditions. Standard error bars are also included for analytical purposes. * = p < 0.05, ** = p < 












Figure 2: Viable S. aureus colonies on Mannitol Salt Agar after 24 hours at 37°C from washed 
biofilms. Biofilms were grown for 24 hours at 37°C under control conditions with our clinical S. 
aureus strain alone and under experimental conditions with our clinical S. aureus strain co-
cultured with one, two, and three times concentrations of A. faecalis. Mean log10 CFU/mL data 
were obtained from three separate trials, and statistical analysis was performed using one-tailed, 
unpaired Student T-tests comparing the control condition to each of the three experimental 
conditions. Standard error bars are also included for analytical purposes. 















(a)                                          (b) 
 
 
(c)             (d)  
     
Figure 3: Gram-stains of biofilms grown for 24 hours and visualized at 100x: (a) S. aureus 
clinical strain (SAC), (b) co-culture of S. aureus clinical and 1x concentration of A. faecalis, (c) 







Confirmation of a Contact-dependent Mechanism 
 To supply further proof that Alcaligenes’ method of inhibition is contact-dependent and 
not due to secretion of an antimicrobial compound only in the presence of a competing organism, 
cell-free supernatant from co-cultures of A. faecalis or A. viscolactis and S. aureus or C. albicans 
were spotted onto lawns of the test organism along with controls of live Alcaligenes cells, 
Alcaligenes supernatant, and S. aureus/C. albicans supernatant. As hypothesized, only live 
Alcaligenes cells formed zones of inhibition on both S. aureus and C. albicans, confirming the 
requirement of live contact of Alcaligenes with its microbial prey (Fig. 4 & 5).  
 
Figure 4: Co-culture-supernatant test: (a) A. faecalis cells, (b) A. faecalis supernatant, (c) C. 
albicans supernatant, (d) A. faecalis - C. albicans co-culture supernatant, (e) A. faecalis cells, (f) 







Figure 5: Co-culture-supernatant test: (a) A. viscolactis cells, (b) A. viscolactis supernatant, (c) 
C. albicans supernatant, (d) A. viscolactis - C. albicans co-culture supernatant, (e) A. viscolactis 
cells, (f) A. viscolactis supernatant, (g) S. aureus supernatant, (h) A. viscolactis - S. aureus co-
culture supernatant. 
 
Spectrum of Alcaligenes Inhibitory Activity  
 While previous research had shown that both A. faecalis and A. viscolactis are significant 
inhibitors of C. albicans and Staphylococcus species, it was still unclear whether they were 
active against other microorganisms. Both Alcaligenes strains were spot-tested on a variety of 
other microbial species (Table 6). A. faecalis was found to be a relatively strong inhibitor of 
members of the genus Bacillus, including the pathogenic B. cereus. (Fig. 6). Interestingly, 
preliminary testing shows that A. faecalis also kills Candida glabrata, though not to the degree 
that it does C. albicans, which may be at least explained in part by C. glabrata’s yeast 
morphology and lack of morphological switching into hyphal form as in C. albicans [45]. This 
would be consistent with previous observations in our lab of decreased inhibition of C. albicans 
in yeast-locked strains. Moreover, Alcaligenes viscolactis exhibited a lesser effect on these 




Shigella dysenteriae, and Shigella sonnei showed a small degree of sensitivity to A. faecalis but 
none to A. viscolactis (Fig. 6). We also noted that the Gram-negative Rhizobium leguminosarum 
was strongly inhibited by both Alcaligenes species, and that it does not appear that A. faecalis 
and A. viscolactis inhibit each other’s growth.  
Table 6: Spot-Test Assays of A. faecalis and A. viscolactis on broad range of organisms (* not 













 B. cereus  ++ - 
 B. megaterium  +++ - 
Gram-positive B. subtilis  +++ + 
 E. faecalis  - - 
 S. aureus  +++ ++ 
 S. pyogenes  -  - 
Fungal 
C. albicans +++ ++ 
C. glabrata + nd*  
 C. freundii  - - 
 E. coli BW20767/prRL27 - - 
 Escherichia coli ATCC #25922 - - 
 Klebsiella aerogenes  - - 
 Klebsiella pneumoniae  + - 
 Proteus vulgaris  - - 
 Pseudomonas aeruginosa  - - 
Gram-negative Pseudomonas denitrificans  -  - 
 Rhizobium leguminosarum +++ +++ 
 Salmonella arizonae  -  - 
 Salmonella typhi  - - 
 Serattia marcescens  - - 
 Shigella boydii  - - 
 Shigella dystenteriae  + - 







Figure 6: Zones of inhibition of A. faecalis on lawns of (a) B. megaterium (b) B. subtilis (c) B. 
cereus (d) R. leguminosarum (e) Candida glabrata.  
 
 




Figure 7: Zones of inhibition of A. viscolactis on lawns of (a) B. subtilis (b) R. leguminosarum.  
 
These observations raise a pertinent question. While both A. faecalis and A. viscolactis 
have been shown to have live-cell dependent, microbicidal effects on a number of organisms, 
what explains the significant difference in their activity when spot-tested on certain species? One 
hypothesis is that incubation at 37°C to allow the test organism to grow may stunt the growth of 
A. viscolactis or its expression of intracellular machinery needed to kill more resistant organisms. 
Results from the biofilm assays appear to contradict this explanation, however. Additionally, its 
lack of motility and slower growth rate compared to A. faecalis may also explain its lesser 
activity when using a spot-test assay, suggesting that co-culture colony counts may be a better 
mechanism for determining spectrum of inhibition for A. viscolactis.  
Mutagenesis with pRL27 
 Transposon mutagenesis is a technique that uses conjugation to transfer a plasmid 
containing a transposon element into the desired bacterium. Once inside the cell, the transposon 
    (a)         (b)               
                            




segment of the plasmid randomly inserts once into the bacterial chromosome with the help of a 
transposase enzyme, disrupting the gene at the point of insertion. This technique is incredibly 
valuable for identification of unknown genes integral for a specific function. In this case, E. coli 
strain BW20767 carrying plasmid vector pRL27 was used for conjugation to transport the Tn5 
transposon into A. faecalis and A. viscolactis [40]. The pRL27 plasmid also contains a Kmr gene, 
which confers Kanamycin resistance to both the donor strain and the mutant upon insertion of 
the transposon [40]. This enables simple isolation of mutants via growth on antibiotic plates. 
Kirby-Bauer testing was performed on E. coli-pRL27 and on both Alcaligenes species to create 









Table 7: Susceptibility Profile of E. coli pRL27, A. faecalis, and A. viscolactis to common 
antibiotics.  
 
 Based on the results, Ampicillin and Kanamycin were chosen as the appropriate 
antibiotics for the selection of mutants. Both Alcaligenes species are resistant to Ampicillin while 
E. coli pRL27 is not, which allows only the growth of Alcaligenes. Since mutants contain the 
KmR gene, treatment with Kanamycin will inhibit growth of all Alcaligenes cells except for 
exconjugants with the transposon inserted into its genome. Despite successful mutagenesis of 
Klebsiella pneumoniae ATCC #13883 using E. coli pRL27 by others in our lab, no mutants of 
Antibiotic  Concentration 
(MCG) 
E. coli pRL27 
Susceptibility  




Ampicillin  10 + - - 
Bacitracin 10 - - - 
Chloramphenicol 30 + + - 
Erythromycin 15 - + - 
Kanamycin 30 - + + 
Novobiocin 5 - n/a + 
Penicillin 10 - - - 
Streptomycin 10 + + - 




either A. faecalis or A. viscolactis were obtained by any of the three techniques outlined earlier 
[46]. While isolated colonies appeared on plates left in the incubator for longer than 48 hours, 
they either failed to grow when re-plated on selective media or were determined to be 
Staphylococcal contaminants by Gram-staining. The repeated occurrence of contaminants 
suggest either a breakdown of antibiotics past 48-72 hours or colonization by a strain of 
Staphylococcus resistant to both antibiotics used. Despite numerous screenings, no true 
Alcaligenes mutants were obtained via transposon mutagenesis.   
In Silico Analysis of A. faecalis Genomic DNA 
 Using NCBI’s genomic database and protein BLAST function, the genomes of several 
fully sequenced A. faecalis strains were analyzed for the presence of T6SS genes. Core genes of 
conserved T6SS components as well as other proteins of unknown function were found clustered 
at a single locus in several A. faecalis strains (Table 8). Of the essential TssA-TssM genes, all 
except for TssH were found in every genome containing the T6SS locus. Whether the sheath 
recycling function of TssH in A. faecalis is not critical to its T6SS functioning or is sometimes 
replaced by another protein is currently unknown. Interestingly, an unidentified protein 
containing a Duf4150 domain was also found within this locus. In certain proteobacteria such as 
Agrobacterium tumefaciens, this N-terminal domain caps the end of the spike formed by VgrG, 
while the C-terminal contains a toxin_43 domain that functions as a DNase [47]. Despite the 
conserved Duf4150 domain, no homology to the toxin_43 domain could be found in A. faecalis, 







Gene/Component Conserved/Proposed Function  Source 
TssA  Baseplate Cianfanelli 
et al.  
Contractile Sheath: Small 
Subunit (TssB)  
Contractile Sheath Cianfanelli 
et al. 
Contractile Sheath: Large 
Subunit (TssC) 
Contractile Sheath Cianfanelli 
et al. 
Hcp (TssD)  Expelled Tube  Cianfanelli 
et al. 
TssE Baseplate Cianfanelli 
et al. 
TssF Baseplate Cianfanelli 
et al. 
TssG Baseplate Cianfanelli 
et al. 
TssH* Sheath Recycling/ATPase Cianfanelli 
et al. 
VgrG (TssI)  Expelled Spike  Cianfanelli 
et al. 
TssJ  Membrane Complex Cianfanelli 
et al. 
TssK Baseplate Cianfanelli 
et al. 
DotU (TssL) Membrane complex Cianfanelli 
et al. 
TssM Membrane complex Cianfanelli 
et al. 
Protein with Duf4150 domain  PAAR analogue - tip 
spike/Effector Toxin 
Bondage 
et al.  
Protein with Duf2169 domain  Links VgrG to Effector Protein Bondage 
et al.  
TagF Post-translational regulation Cianfanelli 
et al. 
Protein with FHA domain Post-translational regulation Cianfanelli 
et al. 
Table 8: T6SS Components Found in A. faecalis genome database and their conserved or 








T6SS in A. faecalis ATCC 8750 and A. viscolactis Wards  
 Due to lack of a complete genome sequence for A. faecalis ATCC #8750, primers were 
first designed to amplify a partial sequence and then the full sequence of the VgrG gene to 
determine if a putative T6SS might be present in our laboratory’s strain. VgrG is an 
approximately 2.3 kb gene that codes for a protein forming the spike of the T6SS. PCR and gel 
electrophoresis confirmed presence of VgrG in A. faecalis ATCC #8750 and our strain of A. 
viscolactis (Fig. 8a & 8b). Additionally, we later successfully amplified the Hcp (TssD) gene in 
both A. faecalis and A. viscolactis (Fig. 8c). The Hcp gene encodes an essential protein that in 
T6SS-containing organisms forms a hexameric inner tube structure that is later expelled upon 
contraction. Because its genome sequence has never been recorded or published, these results are 
the first to our knowledge that show evidence of a T6SS in A. viscolactis, further pointing to the 












         (a)       (b)             (c)  
Figure 8: (a): Amplification of small VgrG fragment (276 bp): Lane 1: 100 bp ladder, lane 2-4: 
A. faecalis gDNA, lane 6-8: A. viscolactis gDNA, (b) Amplification of large VgrG seq. (2.276 
kb): Lane 1:  λ DNA-HindIII ladder, Lane 2: A. faecalis gDNA, Lane 3: A. viscolactis gDNA, (c) 
Amplification of Hcp (388 bp): Lane 1: 100 bp ladder, Lane 2: A. faecalis gDNA, Lane 3: A. 
viscolactis gDNA. 
 1    2   3    4    5   6    7   8 
√ç  




 Sequencing of VgrG 
Forward and reverse nucleotide sequences were merged using Emboss Merger and 
compared to sequences in the NCBI genome database using BLAST. Th 
The 273 bp sequence obtained from A. faecalis ATCC 8750 shared a 98.84% similarity 
with the VgrG sequences from A. faecalis strains DSM30030 and FDAARGOS_491 and greater 
than 92% similarity to other strains. The 275 BP sequence obtained from A. viscolactis shared 
99.27% similarity with the VgrG sequences from A. faecalis strains DSM30030 and 
FDAARGOS_491 and greater than 92% similarity to other A. faecalis strains. Using EMBOSS 
Needle, both sequences were aligned and analyzed, and comparison revealed a 97.1% similarity 
between the obtained VgrG sequences of A faecalis and A. viscolactis. While only a small 
segment was successfully sequenced, these results confirm that the designed primers amplified 
the VgrG gene and points to a high degree of similarity between the VgrG genes of both A. 
faecalis and A. viscolactis (Fig. 9).  
 
Figure 9: Alignment of A. faecalis and A. viscolactis partial VgrG sequences obtained from PCR 






2 kb 2 kb  
Construction and Transfer of a VgrG Deletion Product via SOE 
 Because the VgrG gene encodes an essential part of the T6SS, construction of a VgrG 
knockout mutant would allow us to determine what role, if any, the T6SS plays in the broad-
spectrum, antimicrobial phenotype displayed by A. faecalis and, by extension, A. viscolactis. 
Using SOE primer pairs, approximately 1000 bp regions flanking VgrG in A. faecalis were 
amplified via PCR (Fig. 10a). A second PCR reaction fused the two segments together, forming 
a deletion product (Fig. 10b). This product was successfully ligated into pEX18Gm and 
transformed into E. coli NEBα5 by heat shock. Blue/white screening and colony PCR both 
confirmed presence of the recombinant plasmid carrying the SOE product (Fig. 10c & 11).  
  
                 
       (a)           (b)              (c) 
Figure 10: Visualization of PCR amplification on 1% agarose gel with NEB 1 kb plus DNA 
ladder: (a) Lanes 2-3: upstream SOE fragment, Lanes 4-5: downstream SOE fragment, (b) Lanes 
2-5: SOE crossover product (c) Lanes 2-6: SOE product in transformed NEBα5 colonies.  
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Figure 11: Blue/White Screening for Recombinant NEBα5 Colonies Containing SOE VgrG 
Deletion Product.  
 
Triparental Mating  
 Despite successful construction and insertion of pEX18GmΔVgrG into NEBα5, 
triparental mating with pRK2013 repeatedly failed to transfer the plasmid to A. faecalis. 
Increasing incubation time to 48 hours and modifying incubation temperature from 37°C to 42°C 
had no effect. Biparental mating with SM10λpir and A. faecalis was also attempted, and 
conjugation was unsuccessful as before. Without the ability to insert plasmids into A. faecalis, 
we were unable to create a VgrG knockout mutant and ascertain whether the putative T6SS of A. 
faecalis is responsible for our observations. Despite hundreds of attempts by members of our lab 
and using multiple methods including conjugation, heat shock, and electroporation, both A. 
faecalis and A. viscolactis have proved resistant to horizontal gene transfer. Despite other 
studies’ success using conjugation and electroporation with A. faecalis, strains other than ATCC 
#8750 were used [48,49]. This raises the question as to whether this strain along with our lab’s 
strain of A. viscolactis possess unknown barriers to the uptake of foreign DNA such as restriction 
enzyme activity [50].  
Transformants with SOE Insert  
Transformants without 




Antibiotic Susceptibility and Phenotypic Profile of Other A. faecalis Strains 
 
 An antibiotic susceptibility profile for two new A. faecalis strains was carried out so that 
a suitable selective media for conjugation could be determined (Table 9). Unlike strain #8750, 
strains C19593, #35655, and Wards were resistant to Streptomycin in addition to Ampicillin, 
Penicillin, and Bacitracin (Fig. 12). While these strains showed the greatest sensitivity to 
Kanamycin, #35655 demonstrated a large decrease in sensitivity to Chloramphenicol, 
Tetracycline, and Erythromycin (Fig 12b). All three strains retained the inhibitory phenotype 
against clinical S. aureus (Fig. 13).  
 












Antibiotic  Concentration 
(MCG) 
A. faecalis C19593 
Susceptibility  
A. faecalis #35655 
Susceptibility 
A. faecalis Wards 
Susceptibility  
Ampicillin  10 - - - 
Bacitracin 2 - - - 
Chloramphenicol 30 + + + 
Erythromycin 15 + + + 
Kanamycin 30 + + + 
Penicillin 10 - - - 
Streptomycin 10 - - - 





   (a)         (b)            (c)  
 
Figure 12: Antibiotic Susceptibility Profile of A. faecalis strains (a) C19593, (b) ATCC #35655, 





  (a)                                                (b)             (c)  
 
Figure 13: Spot-tests of A. faecalis strains (a) C19593, (b) ATCC #35655, and (c) Ward’s on 














 Due to the rise of drug-resistance in bacterial and fungal species, the search for 
innovative approaches to combating these often pathogenic organisms is urgent. The realm of 
polymicrobial interactions is particularly promising as organisms have often developed 
antimicrobial mechanisms to outcompete other species. One such system can be found in 
Alcaligenes faecalis and Alcaligenes viscolactis, which has been found to inhibit S. aureus and 
C. albicans via a microbicidal, contact-dependent mechanism. This thesis builds on these 
previous findings, showing that both Alcaligenes species retain this ability when grown in a 
biofilm with S. aureus and kill a broad range of organisms including C. glabrata and a variety of 
Gram-positive and even Gram-negative bacteria. Additionally, it provides preliminary evidence 
for the potential existence of a putative T6SS in A. faecalis and A. viscolactis, which may be 
responsible for our observations. If implicated, this T6SS would be unique due its ability to 
target not only eukaryotic Candida species and certain Gram-negative bacteria but also a range 
of Gram-positive organisms, an ability not currently considered possible in the studied T6SS of 
other bacteria [35]. Future studies of the T6SS in Alcaligenes faecalis may also lead to discovery 
of a new class of effector molecules. Because of a consistent inability to induce plasmid transfer 
via conjugation and other forms of gene transfer, the exact mechanism for Alcaligenes’ 
inhibitory effect remains elusive, and an entirely unknown system may be at play. Future 
directions include RNA isolation and analysis for upregulation of T6SS genes during co-cultures 
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